Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMORLTH)

Drug Name

PDGF receptor tyrosine kinase inhibitor III Drug Info

Synonyms

PDGFR Tyrosine Kinase Inhibitor III; PDGF Receptor Tyrosine Kinase Inhibitor III; CHEMBL102346; 205254-94-0; 4-(6,7-dimethoxyquinazolin-4-yl)-N-(4-phenoxyphenyl)piperazine-1-carboxamide; 4-(6,7-Dimethoxy-4-quinazolinyl)-N-(4-phenoxyphenyl)-1-piperazinecarboxamide; N-(4-Phenoxyphenyl)-4-(6,7-dimethoxyquinazoline-4-yl)piperazine-1-carboxamide; SCHEMBL2592017; GTPL6019; CTK8E8815; DTXSID20447892; CHEBI:143127; HMS3229I09; IN1156; HSCI1_000345; BDBM50115301; CCG-206772; NCGC00185729-01; ACM205254940; RT-014972; J-013383

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 10907042
ChEBI ID: CHEBI:143127
CAS Number: CAS 205254-94-0
TTD Drug ID: DMORLTH

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Patented Agent(s)

Download the Complete Related Drug List

Drug(s) Targeting Platelet-derived growth factor receptor beta (PDGFRB)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sorafenib	DMS8IFC	Adenocarcinoma	2D40	Approved	[2]
Romiplostim	DM3U7SZ	Thrombocytopenia	3B64	Approved	[3]
Becaplermin	DM1R5X4	Diabetic complication	5A2Y	Approved	[4]
E-3810	DM42PFT	Solid tumour/cancer	2A00-2F9Z	Phase 3	[5]
Famitinib	DMSFWT7	Solid tumour/cancer	2A00-2F9Z	Phase 2	[6]
XL-820	DMMHX9K	Solid tumour/cancer	2A00-2F9Z	Phase 2	[7]
MK-2461	DM21WBH	Alzheimer disease	8A20	Phase 1/2	[8]
SNN-0031	DM2X3BR	Brain injury	NA07.Z	Phase 1/2	[9]
TAK-593	DMNFZOT	Solid tumour/cancer	2A00-2F9Z	Phase 1	[10]
Pyridine derivative 18	DMBZMYT	N. A.	N. A.	Patented	[11]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Platelet-derived growth factor receptor beta (PDGFRB)	TTI7421	PGFRB_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	Potent and selective inhibitors of platelet-derived growth factor receptor phosphorylation. 3. Replacement of quinazoline moiety and improvement of metabolic polymorphism of 4-[4-(N-substituted (thio)carbamoyl)-1-piperazinyl]-6,7-dimethoxyquinazoline derivatives. J Med Chem. 2003 Nov 6;46(23):4910-25.
2	Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling.Mol Cancer Ther.2008 Oct;7(10):3129-40.
3	Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel... J Med Chem. 2003 Mar 27;46(7):1116-9.
4	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
5	E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models. Cancer Res. 2011 Feb 15;71(4):1396-405.
6	Metabolism and bioactivation of famitinib, a novel inhibitor of receptor tyrosine kinase, in cancer patients. Br J Pharmacol. 2013 Apr;168(7):1687-706.
7	National Cancer Institute Drug Dictionary (drug id 452042).
8	MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor. Cancer Res. 2010 Feb 15;70(4):1524-33.
9	Company report (Neuronova)
10	Biochemical characterization of TAK-593, a novel VEGFR/PDGFR inhibitor with a two-step slow binding mechanism. Biochemistry. 2011 Feb 8;50(5):738-51.
11	RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99.